For patients diagnosed with Amyotrophic Lateral Sclerosis (ALS), the clinical heterogeneity of disease presentation and progression continues to confound the identification of robust outcome measures and biomarkers that can be used as surrogates of progression to provide faster and improved decision-making during clinical trials. To overcome this limitation we developed a non-invasive imaging strategy, termed MRI Cytography (MRC) that is uniquely sensitive to abnormal muscle cytoarchitecture. In a preclinical model of ALS, MRC was able to reliably differentiate between normal and degenerated muscle microstructure.
This abstract and the presentation materials are available to members only; a login is required.